Seminars in Oncology
Volume 30, Issue 6 , Pages 749-762 , December 2003

The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research

  • Hope S Rugo

      Affiliations

    • Department of Medicine, University of California Comprehensive Cancer Center, San Francisco, CA, USA
    • Corresponding Author InformationAddress reprint requests to Hope S. Rugo, MD, Clinical Professor of Medicine, University of California Comprehensive Cancer Center, 1600 Divisidero Ave, 2nd Floor, San Francisco, CA 94115, USA
    • ,
  • Tim Ahles

      Affiliations

    • Department of Psychiatry and Center for Psycho-Oncology Research, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

References 

  1. Baum M, Ravdin PM. Decision-making in early breast cancer (Guidelines and decision tools). Eur J Cancer. 2002;38:745–749
  2. Whelan T, Sawka C, Levine M, et al.  Helping patients make informed choices (A randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer). J Natl Cancer Inst. 2003;95:581–587
  3. Langer AS. Side effects, quality-of-life issues, and trade-offs (The patient perspective). J Natl Cancer Inst Monogr. 2001;30:125–129
  4. Jansen SJ, Kievit J, Nooij MA, et al.  Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer (Is treatment worthwhile?). Br J Cancer. 2001;84:1577–1585
  5. Lindley C, Vasa S, Sawyer W, et al.  Quality of life and preferences for treatment following systemic adjuvant therapy for early stage breast cancer. J Clin Oncol. 1998;16:1380–1387
  6. Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease (II. Affective and cognitive effects of chemotherapy in cancer patients). Am J Psychiatry. 1980;137:597–601
  7. Oxman TE, Silberfarb PM. Serial cognitive testing in cancer patients receiving chemotherapy. Am J Psychiatry. 1980;137:1263–1265
  8. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001;19:812–820
  9. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Huntingt). 2000;14:75–79
  10. Brown PD, Buckner JC, O’Fallon JR, et al.  Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein Mini-Mental State Examination. J Clin Oncol. 2003;21:2519–2524
  11. Ahles TA, Silberfarb PM, Herndon J, et al.  Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin (A study by the Cancer and Leukemia Group B). J Clin Oncol. 1998;16:1954–1960
  12. Goodwin PJ, Black JT, Bordeleau LJ, et al.  Health-related quality-of-life measurement in randomized clinical trials in breast cancer—Taking stock. J Natl Cancer Inst. 2003;95:263–281
  13. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function (Current knowledge and research directions). J Natl Cancer Inst. 2003;95:190–197
  14. Ahles TA, Saykin AJ. Breast cancer chemotherapy-related cognitive dysfunction. Clin Breast Cancer. 2002;3(suppl 3):S84–90
  15. Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Huntingt). 2001;15:613–618
  16. Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer (A new dose-limiting effect?). J Natl Cancer Inst. 1998;90:182–183
  17. Wesnes K. Assessing cognitive function in clinical trials (Latest developments and future directions). Drug Discov Today. 2002;7:29–35
  18. President’s Cancer Panel . Cancer care issues in the United States (Quality of care, quality of life). Report of the Chairman, President’s Cancer Panel, 1988 Bethesda, MD: National Cancer Program, National Cancer Institute; 1999; (available on-line)
  19. Ferrell BR, Hassey Dow K. Quality of life among long-term cancer survivors. Oncology (Huntingt). 1997;11:565–576
  20. Cimprich B. Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs. 1999;22:185–194
  21. Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nurs Res. 2001;50:86–94
  22. Lee-Jones C, Humphris G, Dixon R, et al.  Fear of cancer recurrence—A literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. Psychooncology. 1997;6:95–105
  23. Bower JE, Ganz PA, Desmond KA, et al.  Fatigue in breast cancer survivors (Occurrence, correlates, and impact on quality of life). J Clin Oncol. 2000;18:743–753
  24. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest. 1995;13:561–566
  25. Bender CM, Paraska KK, Sereika SM, et al.  Cognitive function and reproductive hormones in adjuvant therapy for breast cancer (A critical review). J Pain Symptom Manage. 2001;21:407–424
  26. Schagen SB, van Dam FS, Muller MJ, et al.  Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–650
  27. Ahles TA, Saykin AJ, Furstenberg CT, et al.  Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–493
  28. Meyers CA, Wefel JS. The use of the Mini-Mental State Examination to assess cognitive functioning in cancer trials (No ifs, ands, buts, or sensitivity). J Clin Oncol. 2003;21:3557–3558
  29. Barton D, Loprinzi C. Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer (The art of the possible). Clin Breast Cancer. 2002;3(suppl 3):S121–127
  30. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–66
  31. van Dam FS, Schagen SB, Muller MJ, et al.  Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer (High-dose versus standard-dose chemotherapy). J Natl Cancer Inst. 1998;90:210–218
  32. Ibbotson T, Maguire P, Selby P, et al.  Screening for anxiety and depression in cancer patients (The effects of disease and treatment). Eur J Cancer. 1994;30A:37–40
  33. Schagen SB, Muller MJ, Boogerd W, et al.  Late effects of adjuvant chemotherapy on cognitive function (A follow-up study in breast cancer patients). Ann Oncol. 2002;13:1387–1397
  34. Brezden CB, Phillips KA, Abdolell M, et al.  Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–2701
  35. Faust D, Fogel BS. The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis. 1989;177:25–31
  36. McNair DM, Lorr M, Droppleman LF. Edits Manual for the Profile of Mood States. San Diego, CA: Edits/Educational and Industrial Testing Service; 1992;
  37. Wagner LI, Cella D, Cashy AH, et al.  Single item screening to detect clinically significant fatigue, pain, distress and anorexia in ambulatory oncology practice. Proc Am Soc Clin Oncol. 2003;22:2122; (abstr)
  38. Tannock I, Tchen N, Juffs H, et al.  Fatigue, menopausal symptoms and cognitive dysfunction associated with adjuvant chemotherapy (First year results of a large prospective controlled study). Breast Cancer Res Treat. 2002;76:549; (abstr)
  39. Woo B, Dibble SL, Piper BF, et al.  Differences in fatigue by treatment methods in women with breast cancer. Oncol Nurs Forum. 1998;25:915–920
  40. Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer patients. Cancer. 2001;92:1694–1698
  41. Lezak M. Neuropsychological Assessment. New York, NY: Oxford Press; 1995;
  42. Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev. 1994;20:191–214
  43. Choi SM, Lee SH, Yang YS, et al.  5-Fluorouracil-induced leukoencephalopathy in patients with breast cancer. J Korean Med Sci. 2001;16:328–334
  44. Cleeland CS, Bennett GJ, Dantzer R, et al.  Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97:2919–2925
  45. Bower JE, Ganz PA, Aziz N, et al.  T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst. 2003;95:1165–1168
  46. Roses AD. Apolipoprotein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis. 1997;4:170–186
  47. Friedman G, Froom P, Sazbon L, et al.  Apolipoprotein E-[epsilon]4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology. 1999;52:244–248
  48. Liberman JN, Stewart WF, Wesnes K, et al.  Apolipoprotein E-[epsilon]4 and short-term recovery from predominantly mild brain injury. Neurology. 2002;58:1038–1044
  49. Haan MN, Shemanski L, Jagust WJ, et al.  The role of APOE E4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282:40–46
  50. Bretsky P, Guralnik JM, Launer L, et al.  The role of APOE-epsilon4 in longitudinal cognitive decline (MacArthur Studies of Successful Aging). Neurology. 2003;60:1077–1081
  51. Ahles TA, Saykin AJ, Noll WW, et al.  The relationship of APOE genotype to neuropsychological perfomance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–619
  52. Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev. 2003;24:133–151
  53. LeBlanc ES, Janowsky J, Chan BKS, et al.  Hormone replacement therapy and cognition (Sytematic review and meta-analysis). JAMA. 2001;285:1489–1499
  54. Hogervorst E, Yaffe K, Richards M, et al.  Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev CD003122. 2002;
  55. Grady D, Yaffe K, Kristof M, et al.  Effect of postmenopausal hormone therapy on cognitive function (The Heart and Estrogen/progestin Replacement Study). Am J Med. 2002;113:543–548
  56. Cockrell JR, Folstein MF. Mini-Mental State Examination (MMSE). Psychopharmacol Bull. 1988;24:689–692
  57. Yaffe K, Lui LY, Grady D, et al.  Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet. 2000;356:708–712
  58. Rapp SR, Espeland MA, Shumaker SA, et al.  Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663–2672
  59. Shumaker SA, Legault C, Thal L, et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women’s Health Initiative Memory Study: A randomized controlled trial. JAMA. 2003;289:2651–2662
  60. Yaffe K, Haan M, Byers A, et al.  Estrogen use, APOE, and cognitive decline (Evidence of gene-environment interaction). Neurology. 2000;54:1949–1954
  61. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000;64:165–176
  62. Yaffe K, Krueger K, Sarkar S, et al.  Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med. 2001;344:1207–1213
  63. Ernst T, Chang L, Cooray D, et al.  The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst. 2002;94:592–597
  64. Ganz PA, Castellon SA, Silverman DH. Estrogen, tamoxifen, and the brain. J Natl Cancer Inst. 2002;94:547–549
  65. Buzdar A. Anastrozole as adjuvant therapy for early-stage breast cancer (Implications of the ATAC trial). Clin Breast Cancer. 2003;4(suppl 1):S42–48
  66. Bulun SE, Zeitoun K, Sasano H, et al.  Aromatase in aging women. Semin Reprod Endocrinol. 1999;17:349–358
  67. Jenkins VA, Fallowfield LJ, Schilling V, et al.  Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?. Breast Cancer Res Treat. 2002;76:548; (abstr)
  68. Royall DR, Mulroy AR, Chiodo LK, et al.  Clock drawing is sensitive to executive control (A comparison of six methods). J Gerontol B Psychol Sci Soc Sci. 1999;54:P328–333
  69. Royall DR, Lauterbach EC, Cummings JL, et al.  Executive control function (A review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association). J Neuropsychiatry Clin Neurosci. 2002;14:377–405
  70. Royall DR, Rauch R, Roman GC, et al.  Frontal MRI findings associated with impairment on the Executive Interview (EXIT25). Exp Aging Res. 2001;27:293–308
  71. Collie A, Maruff P, Makdissi M, et al.  CogSport (Reliability and correlation with conventional cognitive tests used in postconcussion medical evaluations). Clin J Sport Med. 2003;13:28–32
  72. Darby D, Maruff P, Collie A, et al.  Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59:1042–1046
  73. Schagen SB, Hamburger HL, Muller MJ, et al.  Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51:159–165
  74. Silverman DH, Castellon SA, Abraham L, et al.  Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive changes. Proc Am Soc Clin Oncol. 2003;22:47; (abstr)
  75. Saykin AJ, Ahles TA, Schoenfeld JD, et al.  Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc. 2003;9:246; (abstr)
  76. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep. 2003;3:215–222
  77. Antoni MH, Antoni MH, Carver CS. Cognitive behavioral stress management intervention and positive psychological changes in breast cancer patients after surgery and their physiological correlates. Proc Am Soc Clin Oncol. 2003;22:3064; (abstr)
  78. Cruess DG, Antoni MH, McGregor BA, et al.  Cognitive-behavioral stress management reduces serum cortisol by enhancing benefit finding among women being treated for early stage breast cancer. Psychosom Med. 2000;62:304–308
  79. Gall TL, Cornblat MW. Breast cancer survivors give voice (A qualitative analysis of spiritual factors in long-term adjustment). Psychooncology. 2002;11:524–535
  80. Masuda S, Oakano M, Yamagishi K, et al.  A novel site of erythropoietin productin. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem. 1994;269:19488–19493
  81. Eid T, Brines M. Recombinant human erythropoietin for neuroprotection (What is the evidence?). Clin Breast Cancer. 2002;3(suppl 3):S109–115
  82. Cerami A, Brines ML, Ghezzi P, et al.  Effects of epoetin alfa on the central nervous system. Semin Oncol. 2001;28:66–70
  83. Brines ML, Ghezzi P, Keenan S, et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526–10531
  84. Ehrenreich H, Hasselblatt M, Dembowski C, et al.  Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495–505
  85. Dawson TM. Preconditioning-mediated neuroprotection through erythropoietin?. Lancet. 2002;359:96–97
  86. O’Shaughnessy J, Vukelja S, Savin M, et al.  Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy (Analysis of 6-month follow-up data). Breast Cancer Res Treat. 2002;76:550; (abstr)
  87. O’Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2002;3(suppl 3):S116–120
  88. Leyland-Jones B. Reflection and reaction. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet. 2003;4:459–460
  89. Hencke M, Laszig R, Rube C, et al.  Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy (Randomized, double-blind, placebo-controlled trial). Lancet. 2003;363:1255–1260
  90. Arcasoy MO, Amin K, Karayal AF, et al.  Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 2002;82:911–918
  91. Yasuda Y, Fujita Y, Matsuo T, et al.  Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis. 2003;24:1021–1029
  92. Meyers CA, Weitzner MA, Valentine AD, et al.  Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol. 1998;16:2522–2527
  93. Thompson SJ, Leigh L, Christensen R, et al.  Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol. 2001;19:1802–1808
  94. Kennedy DO, Scholey AB, Wesnes KA. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav. 2002;75:739–751

☆ Supported in part by a grant (R01 CA87845) from the Office of Cancer Survivorship, National Cancer Institute, Bethesda, MD.

PII: S0093-7754(03)00479-2

doi: 10.1053/j.seminoncol.2003.09.008

Seminars in Oncology
Volume 30, Issue 6 , Pages 749-762 , December 2003

Article Tools